{"id":3271,"date":"2025-10-06T05:52:40","date_gmt":"2025-10-06T05:52:40","guid":{"rendered":"https:\/\/genoks.com.tr\/docs\/genoxhere-breast-ovarian-en\/"},"modified":"2026-05-02T05:14:18","modified_gmt":"2026-05-02T05:14:18","password":"","slug":"genoxhere-breast-ovarian-en","status":"publish","type":"docs","link":"https:\/\/genoks.com.tr\/en\/docs\/genoxhere-breast-ovarian-en\/","title":{"rendered":"What is GenoXhere Breast and Ovarian Cancer Panel?"},"content":{"rendered":"

<\/p>\n

GenoXhere Breast and Ovarian Cancer Panel.<\/strong> Comprehensive germline panel for hereditary breast-ovarian cancer assessment, covering BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C, RAD51D, BRIP1, TP53, PTEN, CDH1, STK11. Indicated per NCCN criteria: early-onset breast cancer (\u226445y), male breast cancer, ovarian cancer (any age), triple-negative \u226460y, family history. Identifies carriers eligible for enhanced surveillance, risk-reducing surgery, and PARP-inhibitor therapy. ACMG\/AMP variant classification + counseling.<\/p>\n

<\/p>\n

Meme\/Over Kanseri Nedir?<\/strong>
\nGenetik ge\u00e7i\u015fli meme over kanseri, meme ve over kanseri i\u00e7in genetik yatk\u0131nl\u0131\u011f\u0131 olan bireylerde g\u00f6r\u00fclen bir kanser t\u00fcr\u00fcd\u00fcr. Bu durum, BRCA1 ve BRCA2 ad\u0131 verilen genlerdeki mutasyonlarla ilgilidir. Bu genlerin mutasyonlar\u0131, meme ve over kanseri riskini artt\u0131rabilir.<\/p>\n

Normalde, BRCA1 ve BRCA2 genleri, h\u00fccrelerin normal i\u015flevlerini d\u00fczenler ve kanser geli\u015fimini \u00f6nler. Ancak bu genlerdeki mutasyonlar, h\u00fccrelerin anormal \u015fekilde b\u00fcy\u00fcmesine ve \u00e7o\u011falmas\u0131na neden olabilir, b\u00f6ylece kanser geli\u015fimi i\u00e7in zemin haz\u0131rlan\u0131r.<\/p>\n

\"Meme

Meme Over Kanseri<\/p><\/div>\n

Genetik ge\u00e7i\u015fli meme over kanseri olan bireylerde, meme ve over kanseri riski \u00e7ok daha y\u00fcksektir. Bu nedenle, BRCA genlerinde mutasyon ta\u015f\u0131yan ki\u015filerin, meme ve over kanseri taramalar\u0131n\u0131 d\u00fczenli olarak yapt\u0131rmalar\u0131, sa\u011fl\u0131kl\u0131 ya\u015fam al\u0131\u015fkanl\u0131klar\u0131 benimsemeleri ve gerekli \u00f6nlemleri almak i\u00e7in uzman hekim ile yak\u0131n i\u015fbirli\u011fi i\u00e7inde olmalar\u0131 \u00f6nemlidir. Ayr\u0131ca, genetik testler yaparak risk fakt\u00f6rlerini \u00f6nceden tespit etmek ve erken m\u00fcdahale ederek kanser riskini azaltmak da m\u00fcmk\u00fcnd\u00fcr.<\/p>\n\n\n\n\n\n\n\n\n
Gen :<\/strong><\/td>\nATM | BARD1 | BRCA1 | BRCA2 | BRIP1 | CDH1 | CHEK2 | EPCAM | MLH1 | MRE11 | MSH2 | MSH6 | MUTYH | NBN | NF1 | PALB2 | PMS2 | PTEN | RAD50 | RAD51C | RAD51D | SMARCA4 | STK11 | TP53<\/td>\n<\/tr>\n
Y\u00f6ntem :<\/strong><\/td>\nNGS<\/td>\n<\/tr>\n
Raporlama S\u00fcresi :<\/strong><\/td>\n8 Hafta (+\/- 2 Hafta)<\/td>\n<\/tr>\n
Prenatal\/ Postnatal:<\/strong><\/strong><\/td>\nPostnatal<\/td>\n<\/tr>\n
Gerekli Numune<\/strong>:<\/td>\nEDTA’l\u0131 Kan (2-4 ml)<\/td>\n<\/tr>\n
Saklama \/ Ta\u015f\u0131ma S\u0131cakl\u0131\u011f\u0131:<\/strong><\/td>\n+ 4C\u00b0\/ + 24C\u00b0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

T\u00fcm genetik testlerimiz “Hasta Onam Formu”<\/strong> ve “KVKK Formu”<\/strong>nun imzalanmas\u0131n\u0131n ard\u0131ndan \u00e7al\u0131\u015f\u0131lmaya ba\u015flan\u0131r.<\/p>\n

\n

Detayl\u0131 Bilgi Almak \u0130\u00e7in Bize Mesaj Atabilirsiniz.<\/strong><\/p>\n\n\n\n
[contact-form-7 id=”710″ title=”genetik ba\u015fvuru”]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Genoks Genetik Hastal\u0131klar De\u011ferlendirme Merkezi T.C. Sa\u011fl\u0131k Bankanl\u0131\u011f\u0131nca denetlenen ve GHDM-SM\/06.15\/01 ruhsat numaras\u0131 ile hizmet veren sa\u011fl\u0131k kurulu\u015fudur. genoks.com.tr web sayfas\u0131nda bulunan bilgiler, genetik de\u011ferlendirme ve\/veya tan\u0131-te\u015fhis ama\u00e7l\u0131 kullan\u0131lmamal\u0131d\u0131r. T\u00fcm i\u00e7erikler bilgilendirme ama\u00e7l\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

GenoXhere Breast and Ovarian Cancer Panel. Comprehensive germline panel for hereditary breast-ovarian cancer assessment, covering BRCA1, BRCA2, PALB2, ATM, CHEK2, RAD51C, RAD51D, BRIP1, TP53, PTEN, CDH1, STK11. Indicated per NCCN criteria: early-onset breast cancer (\u226445y), male breast cancer, ovarian cancer [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"doc_category":[204],"doc_tag":[105,106],"class_list":["post-3271","docs","type-docs","status-publish","hentry","doc_category-genoks-gdhm-genetic-tests","doc_tag-kalitsal","doc_tag-kanser"],"aioseo_notices":[],"year_month":"2026-05","word_count":403,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"admin","author_nicename":"admin","author_url":"https:\/\/genoks.com.tr\/en\/author\/admin\/"},"doc_category_info":[{"term_name":"Genoks GDHM Genetic Tests","term_url":"https:\/\/genoks.com.tr\/en\/docs-category\/genoks-gdhm-genetic-tests\/"}],"doc_tag_info":[{"term_name":"Kal\u0131tsal","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kalitsal\/"},{"term_name":"kanser","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kanser\/"}],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t